Background: It is well known that the occurrence of bleeding increases in-hospital mortality in patients with acute coronary syndromes (ACS), and there is a good correlation between bleeding risk scores and bleeding incidence. However, the role of bleeding risk score as mortality predictor is poorly studied.
Introduction
The administration of an adequate and intensive antithrombotic treatment while minimizing bleeding complications presents a major challenge to the effective management of Acute Coronary Syndromes (ACS). In the last decade, antithrombotic regimen options have increased substantially, resulting in numerous unique combinations of the available drugs. Previously, bleeding complications were considered to be a manageable "side effect" of antithrombotic therapy. However, the development of increasingly potent drugs along with concomitant utilization of antithrombotic therapies, has raised concern for bleeding risk, as there is also mounting evidence to suggest an independent association between bleeding complications and other detrimental outcomes in patients with ACS, including higher rates of reinfarction, stroke and death [1] [2] [3] [4] [5] .
The development of effective tools for predicting patient bleeding risk may help in therapeutic decision making to maximize the benefits and minimize the risk of bleeding associated with antithrombotics. Although there are well established models for ischemic complications risk stratification as TIMI, GRACE, and PURSUIT, among others, tools for predicting the bleeding risk are less common. Several studies identified bleeding risk factors for complications but most did not use them to develop a stratification tool for predict bleeding [6] [7] [8] . The demonstration that a more intensive antithrombotic regimen increases bleeding, which in turn increases ischemic events, has led investigators to conclude that antithrombotic treatment in patients with ACS should be personalized 9 . The recently published American College of Cardiology/American Heart Association 2011 focused update of the guidelines for the management of patients with unstable angina/non-STelevation myocardial infarction (NSTEMI) reiterates the importance of balancing antithrombotic strategies with the bleeding risk 10 . Actually, despite more aggressive treatment, bleeding rates did not increase over time, suggesting that clinicians are better tailoring antithrombotic therapy to each patient, which support the idea that better and more reliable bleeding scores would be welcome 11 . On the other hand, is is well demonstrated the correlation between bleeding and in-hospital mortality, and between bleeding scores and incidence of bleeding; however, the predictive value of bleeding risk score for in-hospital mortality is poorly studied.
We contend that valuable advancements are obtained by continually developing simpler and improved calculation methods. Recently, Mehran et al 8 published a simple and easy to assess tool for bleeding risk stratification. They combined the ACUITY and HORIZONS-AMI data, both contemporary and complimentary ACS trials, and proposed a score comprised of 6 baseline factors (gender, age, creatinine, leukocyte, anemia, type of ACS) and 1 modifiable parameter based on antithrombotic regime (heparin + GP IIb/IIIa inhibitor or bivalirudin) 8 . The main purpose of the present study was to evaluate the role of this score as in-hospital mortality predictor in a cohort of patients with ACS treated in a single cardiology tertiary center, comparing its value in STEMI and non-ST-elevation ACS.
Methods
We included 1,655 patients with ACS (547 with ST-elevation ACS and 1,118 with non-ST-elevation ACS). The bleeding score was calculated prospectively in 249 patients and retrospectively in the remaining 1,416. The mean age of the population was 64.3 ± 12.6 years and 67% were male. It is important to note that because bivaluridin is not available in Brazil, the component of the score regarding antithrombotic therapy was always zero. Despite that just 48.1% of the total population was administered with IIb/IIIa inhibitors, there were no significant differences between the groups with or without IIb/IIIa inhibitors with respect to the role of the bleeding score as a mortality or bleeding predictor. For the developed univariate analyses regarding the correlation between bleeding score and mortality or in-hospital bleeding, the Mann-Whitney U test was applied. The Chi-square test was applied for the comparison between categorical variables.
Statistical Analyses
Multivariate stepwise logistic regression models with 0.05 for entry and 0.10 for removal were applied in order to adjust the results for confounding factors. Mortality was the dependent variable, and the baseline and in-hospital variables listed in Table  1 were included as independent variables (except age and gender, which were already included in the bleeding score). Different models were constructed to better analyze the influence of the bleeding score on mortality. The first envisioned scenario was at the patient's hospital arrival where the models in this situation included baseline variables for the global population and the corresponding TIMI risk scores 12, 13 in the subgroups with or without ST-elevation ACS. In order to analyze the influence of in-hospital invasive therapies on the obtained results, a second set of analyses were developed in the same subgroups, with the inclusion of primary angioplasty, non-primary angioplasty, and surgical revascularization in the models.
Finally, the discriminatory power of the bleeding score and the TIMI risk scores as in-hospital mortality predictors was analyzed by Receiver Operator Characteristic (ROC) curves, with the DeLong method 14 , being applied for the statistical comparisons between the curves.
All the above analyses were developed separately for the whole population and also for the ST-elevation ACS and non-ST-elevation ACS. 
Results
The characteristics of the population are depicted in Table 1 . The median bleeding score was 18; from the analyzed population, 14.8% were classified as low risk, 20.3% as medium risk, 24.3% as high risk, and 40.8% as very high risk. One third of the patient population had diabetes, another third previous myocardial infarction, 43.3% were submitted previously to surgical or catheter revascularization, and 73% were revascularized during the present hospitalization. Our patient population was comprised of a typical contemporary population commonly seen in a tertiary cardiology center.
Correlation between bleeding score and in-hospital mortality Univariate analyses showed highly significant correlations between bleeding score and mortality. As shown in Figure 1 As expected, the correlation between bleeding and mortality was also statistically significant (p < 0.001, OR = 5.296) as was the correlation between bleeding score and in-hospital bleeding (p < 0.001, OR = 1.058). Finally, for patients with ST-elevation ACS and with non-ST-elevation ACS, the correlations between the respective TIMI risk scores with mortality were also significant (p < 0.001, OR = 1.586 and p < 0.001, OR = 1.454, respectively).
The main results of the adjusted models are shown in Tables 2, 3 and 4. The bleeding score correlated significantly and independently with mortality in all models, however, the TIMI risk score showed a stronger correlation with mortality than the bleeding score for patients with ST-elevation myocardial infarction. Conversely, the bleeding score showed a better correlation relative to the TIMI risk score for patients with non-ST-elevation ACS. Importantly, the inclusion of in-hospital bleeding in the final models did not change the results for the bleeding score where p < 0.001 (OR = 1.123) for the whole population, and p-values of 0.050 (OR = 1.045) and < 0.001 (OR = 1.146), respectively, were obtained for patients with or without ST-elevation ACS. These findings are further evaluated in the following ROC curve analyses (Figure 2 ).
Discriminatory value of bleeding score and TIMI risk scores for in-hospital mortality prediction Figure 2 shows the ROC curve for bleeding score for the whole population. As can be seen, this score is a good predictor of in-hospital mortality, showing an area under the curve (AUC) of 0.753. Table 5 shows the comparison of the AUC for bleeding score and TIMI risk score in the subgroups with and without ST-elevation ACS. As suggested by the multivariate analyses, in comparison with the respective TIMI scores the bleeding score is a better predictor of in-hospital mortality for patients without ST-elevation ACS and, vice versa, is a worse mortality predictor in the population with ST-elevation ACS.
Discussion
Different bleeding scores have been proposed in order to better evaluate patients with ACS, allowing the attending physician to better utilize the available antithrombotic therapies. In common, these bleeding scores show excellent correlation with bleeding 1, 6, 8 . However, there are important differences between them regarding their complexity and difficulty of utilization. The score proposed by Mehran et al 8 , and tested in the present paper, is one of the most user-friendly in the literature, and in this population derived from a tertiary center, also showed excellent correlation with bleeding.
In our databank the definition for bleeding is broad, and takes any bleeding requiring specific action from the staff including that for surgery for pseudo aneurysm, transfusion, or that requiring a third party opinion -generally a angiologist/vascular surgeon, neurologist or hematologist into account. Interestingly, the observed incidence of in-hospital bleeding in the present population was the same as described by Mehran et al 8 for 30 days (4.3%,) and close to the percentage described in the GRACE Registry (3.9%) for in-hospital major bleeding 1 .
On the other hand, it is well demonstrated that the presence of bleeding during hospitalization in patients with ACS increases significantly the incidence of ischemic events, including mortality, in this population 4, 5, 15 . Consequently, we found a significant correlation between the presence of bleeding and mortality, with an odds-ratio > 5.
Regarding the TIMI risk scores in both, ACS with or without ST-segment elevation, they show clear correlations with mortality/ischemic events, which could also be demonstrated in the present population 12, 13 . The discriminatory power of the non-ST-elevation ACS TIMI risk score to predict ischemic events (all-cause mortality, myocardial infarction, urgent revascularization) was 0.65 13 , being 0.62 in the present publication, that took into account only all-cause mortality. The ST-elevation myocardial infarction TIMI risk score was studied in a broad population of patients included in the North-American registry of myocardial infarction (submitted to fibrinolysis, primary angioplasty or without reperfusion) 16 ; overall, its discriminatory power for all-cause mortality was 0.74, being 0.798 in the present study. This value is near the 0.83 proposed by Diamond 17 as the maximal value for a perfectly calibrated prediction rule, while at the same time the authors explain that higher values are possible but come at the cost of poorer calibration.
An analysis of bleeding score as a mortality risk factor, and its relationship with TIMI risk scores and in-hospital bleeding, have not been published previously. Our major findings were 1) The bleeding risk score proposed by Mehran et al 8 is an excellent predictor of in-hospital mortality in patients with acute coronary syndromes and 2) Regarding in-hospital mortality when compared with the TIMI risk scores, the bleeding risk score was more reliable than the corresponding TIMI risk score for patients with non-ST-elevation ACS, and performed worse as an indicator in patients with ST-elevation myocardial infarction. However, we found that both variables correlated significantly and independently with mortality in the broad spectrum of patients with ACS that we analyzed for this study. Interestingly, despite the excellent correlation between the bleeding risk score and the observed bleeding, both variables correlated significantly and independently with in-hospital mortality. These findings suggest that other variables included in the bleeding score could influence in-hospital mortality independently of bleeding itself, as could be the case for age.
Limitations of the Study
As with any databank-derived study, it is possible that confounders not included in the adjusted models could have influenced the results with respect to the correlation of the bleeding score and mortality. Certainly the ROC curve analyses, which showed excellent discriminatory power of the bleeding score to predict mortality, is useful in order to give a more reliable and complete answer
